Jeff Aguilar (@jeffMDMBA) header
Jeff Aguilar (@jeffMDMBA) profile picture

🇵🇭🇨🇦IM PGY-2 DMC Sinai-Grace | Research @Karmanoscancer. #hematology, #oncology #IMG

Canada
Joined September 2017
Photo by Jeff Aguilar (@jeffMDMBA)Photo by Jeff Aguilar (@jeffMDMBA)Photo by Jeff Aguilar (@jeffMDMBA)Photo by Jeff Aguilar (@jeffMDMBA)Photo by Jeff Aguilar (@jeffMDMBA)Photo by Jeff Aguilar (@jeffMDMBA)Photo by Jeff Aguilar (@jeffMDMBA)Photo by Jeff Aguilar (@jeffMDMBA)Photo by Jeff Aguilar (@jeffMDMBA)Photo by Jeff Aguilar (@jeffMDMBA)
How does leukaemia develop? 🩸 How long does it take? ⏳ 🌟 Our paper, started back when I was a PhD student in @jrblundell’s lab, is out today in @Nature 🌟 Yearly blood samples from women who developed AML in later life let us trace it back decades 👇 doi.org/10.1038/s41586-026-1…
25
132
22
477
40,178
Jeff Aguilar retweeted
Artificial intelligence agents in cancer research and oncology - Truhn 2026, Nature Reviews Cancer
10
117
6
561
45,863
Thrilled to announce our meta-analysis and systematic review on myeloid sarcoma is now published in @Cancers_MDPI ! Check out our clinically relevant results here: doi.org/10.3390/cancers17243… #leukemia #myeloidsarcoma #CancerResearch
Excited to share our new 📃 on myeloid sarcoma (MS), where we found frequent (56%) NGS discordance between bone marrow and MS tissue and exclusive presence of NPM1 mutations in MS- which should be checked routinely and targeted! @jeffMDMBA @malignantheme doi.org/10.3390/cancers17243…
2
4
177
Getting ready for the Ham-Wasserman lecture with the boys and our favourite cells @DakshinPadman @sikchoh #ASH25
4
259
Congratulations @OpsBug @abdulmoiz82! Differential prognostic impact of NPM1-MT AML underscores the need for age-adapted risk stratification models @MDPIOpenAccess @jeffMDMBA @NanjaSushmitha @JulieBoerner2 @CarmeloGurnari @Bahaj_MD @tariqkewan @VisconteValeria
2
9
17
1,780
Excited to share our latest findings! Join us this evening at Poster 2768 as @sandhyadhiman5 presents on menin interaction and nuclear export inhibition in NPM1-mutant AML.#ASH24 @ASH_hematology
1
4
9
724
How do TP53 configurations evolve with treatment and impact prognosis? @DakshinPadman will present intriguing findings tonight. Don’t miss it! #ASH24 @ASH_hematology @waynestate @karmanoscancer @KarmanosHemeOnc @OpsBug @jeffMDMBA
3
6
538
Excited to present our poster on mutational site-specificity and concordance/discordance characteristics in myeloid sarcoma here at #ASCO24 ! Big thanks to mentor @malignantheme cc: @DakshinPadman @karmanoscancer @IMG_Oncologists #leusm
5
11
897
Excited to present our work on Telomere biology gene mutations in MDS and IPSS-M(R) work here! @OpsBug @jeffMDMBA @karmanoscancer
#ESHMDS2024: OUR TEAM IS READY TO WELCOME YOU IN BUDAPEST! Registration opens at 7:30 am tomorrow! bit.ly/3MClLmS April 12-14, 2024 9th Translational Research Conference: MYELODYSPLASTIC SYNDROMES Chairs: @FenauxP @GoetzeKatharina @MikkaelSekeres #ESHCONFERENCES #MDSsm
4
15
1,126
Check out our interesting case report of pancytopenia post mild COVID recovery, featured as the cover story of Hematology Reports Vol. 16, Issue 1 @malignantheme @OpsBug
🌟🌟Two cases of new-onset PNH/aplastic anemia syndrome and aplastic anemia associated with COVID-19, but but the exact mechanism is still unknown. 🔗mdpi.com/2038-8330/16/1/5 👨‍🔬 By Dr. Suresh Balasubramanian @MDPIOpenAccess
1
3
428
What a wonderful story put together by Dr.Kubota! Congrats to Dr. Maciejewski’s Lab ⁦@ClevelandClinic⁩ Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting | ⁦@NatureComms⁩ nature.com/articles/s41467-0…
13
32
3,434
“If you're not using it, you're like those kids who are coming out of college in 1990 and still they’re not learning how to use word processors.”
1
211
Some key findings for OS based on ELN favourable risk and secondary type mutations on NPM1 mt in De novo and t-AML #ASH23 ash.confex.com/ash/2023/webp…
Replying to @OpsBug
@opsbug discussing now on the impact of NPM1 mutation across denovo and t-AML settings! #ASH23
2
221
Does NPM1 MT convey similar impact when in De Novo vs T/sAML? 👇✅ your 🗓️ for this session that begins at 245PM today! #ASH23 @OpsBug @jeffMDMBA @NanjaSushmitha @LakshmiBPotluri
2
7
343
#ASH23 News Daily Monday AM edition is out. Our piece ‘It’s time to sp(l)ice things up’ covers fantastic work by @SBenbarche @AbdelWahablab, which was presented at #ASH23 Plenary Session. @ASH_hematology. Read it here: ashpublications.org/ashnewsd… @NatashaSzuber @JuliPerezBot
1
5
16
1,338
Our #ASH23 poster on meta-analysis of myeloid sarcoma, #3811, in 900s section. One of the largest cohorts of myeloid sarcoma, pooled to gain insights on the disease! Cc: @DakshinPadman #ASHKudos to mentor and PI @malignantheme ash.confex.com/ash/2023/webp…
5
9
697
#ASHKudos to this morning’s presentations in Emerging Tools, Techniques and AI in Hematology. Exciting to learn more about machine learning and computational models under development #ASH23
161
Epigenetic aging and age acceleration can be potential biomarkers for targeted therapy in AML. More interesting data being shared by @OpsBug @jeffMDMBA #ASH23
3
13
479
2 oral presentations and 5 posters at ASH 2023 from us! More details after the embargo! Felicitations! @OpsBug @NanjaSushmitha @LBP0818 @jeffMDMBA @DakshinPadman @karmanoscancer
4
5
1
27
2,917
Replying to @NanjaSushmitha
@NanjaSushmitha will present our findings on "Clonal hematopoiesis and response to ICI in HL" at the MSHO 2023 annual meeting. Congrats on the merit award! @KarmanosHemeOnc @karmanoscancer @OpsBug @jeffMDMBA @JulieBoerner2
3
1
7
1,176